论文部分内容阅读
目的探讨氨溴索预防早产儿肺透明膜病的临床效果。方法本次共选择80例早产儿作研究对象,均为我院新生儿科2011年1月至2012年6月收治的早产儿,采用数字表抽取法随机分组,就常规治疗(对照组,n=40)与加用氨溴索治疗(观察组,n=40)效果进行比较。结果观察组统计示早产儿肺透明膜病1例,占2.5%,对照组经统计示为8例,占20%,差异有显著统计学意义(P<0.05)。观察组肺出血、肺部感染、呼吸衰竭、颅内出血、动脉导管未闭并发症发生率均低于对照组,其中呼吸衰竭具统计差异(P<0.05)。结论采用氨溴索防治早产儿肺透明膜病,可显著降低其发生率,且具较高安全性,并可减少其他并发症的发生,具有非常积极的临床应用价值。
Objective To investigate the clinical effect of ambroxol on preventing hyaline membrane disease in preterm infants. Methods A total of 80 preterm infants were selected as study subjects. All of them were premature infants admitted to neonatal department of our hospital from January 2011 to June 2012. The patients were randomly divided into three groups according to the routine treatment (n = 40) compared with the addition of ambroxol (observation group, n = 40). Results The observation group showed 1 case of hyaline membrane disease in preterm infants, accounting for 2.5%. The control group showed 8 cases (20%), the difference was statistically significant (P <0.05). The incidences of pulmonary hemorrhage, pulmonary infection, respiratory failure, intracranial hemorrhage and patent ductus arteriosus in observation group were lower than those in control group, with respiratory failure statistically significant (P <0.05). Conclusion Ambroxol to prevent and treat preterm infants with hyaline membrane disease can significantly reduce its incidence, and with high safety, and can reduce the incidence of other complications, has a very positive clinical value.